NASDAQ:DNAY Telesis Bio (DNAY) Stock Forecast, Price & News $1.30 +0.10 (+8.33%) (As of 01/3/2023) Add Compare Share Share Today's Range$1.20▼$1.3150-Day Range$1.52▼$3.0252-Week Range$1.08▼$11.02Volume19,900 shsAverage Volume54,063 shsMarket Capitalization$38.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Telesis Bio MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside284.6% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.85) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector514th out of 980 stocksAnalytical Instruments Industry16th out of 27 stocks 3.5 Analyst's Opinion Consensus RatingTelesis Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Telesis Bio has a forecasted upside of 284.6% from its current price of $1.30.Amount of Analyst CoverageTelesis Bio has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DNAY. Previous Next 0.0 Dividend Strength Dividend YieldTelesis Bio does not currently pay a dividend.Dividend GrowthTelesis Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DNAY. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Telesis Bio to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Telesis Bio insiders have not sold or bought any company stock.Percentage Held by Insiders30.20% of the stock of Telesis Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.66% of the stock of Telesis Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Telesis Bio are expected to grow in the coming year, from ($1.85) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Telesis Bio is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telesis Bio is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelesis Bio has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Telesis Bio (NASDAQ:DNAY) StockCodex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Read More Receive DNAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address DNAY Stock News HeadlinesMay 12, 2023 | marketbeat.comBlue Bird, First Solar rise; Harrow Health, Telesis Bio fallStocks that traded heavily or had substantial price changes Friday: Blue Bird, First Solar rise; Harrow Health, Telesis Bio fallMay 11, 2023 | investing.comTelesis Bio Inc (TBIO)June 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.April 12, 2023 | forbes.comThis Desktop Machine Is About To Transform The Decades-Old DNA Synthesis IndustryMarch 31, 2023 | marketwatch.comTelesis Bio Shares Rise 10% After Release of Two New DNA KitsMarch 22, 2023 | marketwatch.comTelesis Bio Shares Climb 35% on 2023 Revenue GuidanceMarch 21, 2023 | sfgate.comTelesis Bio: Q4 Earnings SnapshotMarch 21, 2023 | finance.yahoo.comTelesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 GuidanceJune 5, 2023 | Edge On The Street (Ad)AI is Unstoppable. Now Is The Time!AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.March 16, 2023 | msn.comShould You Buy Telesis Bio (TBIO) After Golden Cross?March 14, 2023 | forbes.comSynthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego FacilityJanuary 3, 2023 | yahoo.comProtalix BioTherapeutics Issues 2023 Letter to StockholdersDecember 14, 2022 | uk.finance.yahoo.comTelesis Bio, Inc. (DNAY)November 21, 2022 | forbes.comCan A Desktop DNA Printer Stomp Out The Next Pandemic?November 12, 2022 | seekingalpha.comTelesis Bio, Inc. (DNAY) Q3 2022 Earnings Call TranscriptNovember 11, 2022 | finance.yahoo.comTelesis Bio, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportNovember 8, 2022 | finance.yahoo.comTelesis Bio Inc. Reports Third Quarter 2022 Financial ResultsOctober 19, 2022 | finance.yahoo.comTelesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrumentOctober 4, 2022 | finanznachrichten.deCodex DNA, Inc.: Codex DNA Expands Application of Proprietary Error Correction TechnologyOctober 4, 2022 | finance.yahoo.comCodex DNA Expands Application of Proprietary Error Correction TechnologySeptember 28, 2022 | seekingalpha.comDNAY Codex DNA, Inc.September 26, 2022 | benzinga.comCodex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, NetherlandsSeptember 26, 2022 | finance.yahoo.comCodex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, NetherlandsSeptember 20, 2022 | finanznachrichten.deCodex DNA, Inc.: Codex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationSeptember 19, 2022 | finance.yahoo.comCodex DNA Debuts Next-Generation Automated Synthetic Biology WorkstationSeptember 18, 2022 | nbcnews.comMore DNA sought from remains of possible Tulsa massacre victimsAugust 26, 2022 | finance.yahoo.comCodex DNA (DNAY) Could Find Support Soon, Here's Why You Should Buy the Stock NowSee More Headlines DNAY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNAY Company Calendar Last Earnings11/08/2021Today6/05/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DNAY CUSIPN/A CIK1850079 Webcodexdna.com Phone858-228-4115FaxN/AEmployees212Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+284.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,960,000.00 Net Margins-251.04% Pretax Margin-250.94% Return on Equity-73.65% Return on Assets-51.19% Debt Debt-to-Equity Ratio0.37 Current Ratio4.86 Quick Ratio4.68 Sales & Book Value Annual Sales$21.04 million Price / Sales1.82 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.42Miscellaneous Outstanding Shares29,522,000Free Float20,606,000Market Cap$38.38 million OptionableNot Optionable Beta1.36 Key ExecutivesDr. Todd R. Nelson MBA (Age 55)Ph.D., Pres, CEO & Director Comp: $876.78kMr. Daniel G. Gibson Ph.D. (Age 45)Chief Technology Officer Comp: $436.54kMr. Eric Esser (Age 52)Chief Operating Officer Richard LepkeDirector of Investor RelationsMr. Robert H. Cutler (Age 54)Chief Legal Officer Ms. Laura B. Puga M.B.A. (Age 42)VP of People & Culture Mr. Decky Goodrich M.B.A.Sr. VP of Commercial OperationsMr. Brent M. HunterExec. OfficerMr. Laurence WardenSr. VP of Engineering & InstrumentationMore ExecutivesKey CompetitorsBerkeley LightsNASDAQ:BLIRapid Micro BiosystemsNASDAQ:RPIDAccelerate DiagnosticsNASDAQ:AXDXSingular Genomics SystemsNASDAQ:OMICPrecipioNASDAQ:PRPOView All CompetitorsInstitutional OwnershipPenn Capital Management Company LLCSold 629,779 shares on 5/16/2023Ownership: 1.844%Susquehanna International Group LLPBought 15,900 shares on 5/16/2023Ownership: 0.000%Two Sigma Investments LPSold 21,382 shares on 5/15/2023Ownership: 0.078%Two Sigma Securities LLCBought 10,515 shares on 5/15/2023Ownership: 0.036%Renaissance Technologies LLCBought 14,294 shares on 5/12/2023Ownership: 0.323%View All Institutional Transactions DNAY Stock - Frequently Asked Questions Should I buy or sell Telesis Bio stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Telesis Bio in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DNAY shares. View DNAY analyst ratings or view top-rated stocks. What is Telesis Bio's stock price forecast for 2023? 1 brokers have issued 1-year target prices for Telesis Bio's shares. Their DNAY share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price. View analysts price targets for DNAY or view top-rated stocks among Wall Street analysts. How have DNAY shares performed in 2023? Telesis Bio's stock was trading at $1.20 on January 1st, 2023. Since then, DNAY stock has increased by 8.3% and is now trading at $1.30. View the best growth stocks for 2023 here. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:DNAY) announced its earnings results on Monday, November, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The company earned $2.79 million during the quarter, compared to the consensus estimate of $2.93 million. Telesis Bio had a negative net margin of 251.04% and a negative trailing twelve-month return on equity of 73.65%. When did Telesis Bio IPO? (DNAY) raised $100 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and KeyBanc Capital Markets served as the underwriters for the IPO. What is Telesis Bio's stock symbol? Telesis Bio trades on the NASDAQ under the ticker symbol "DNAY." Who are Telesis Bio's major shareholders? Telesis Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Penn Capital Management Company LLC (1.84%), Penbrook Management LLC (1.16%), Renaissance Technologies LLC (0.32%), Vontobel Holding Ltd. (0.17%), Susquehanna International Group LLP (0.00%) and Two Sigma Investments LP (0.08%). How do I buy shares of Telesis Bio? Shares of DNAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Telesis Bio's stock price today? One share of DNAY stock can currently be purchased for approximately $1.30. How much money does Telesis Bio make? Telesis Bio (NASDAQ:DNAY) has a market capitalization of $38.38 million and generates $21.04 million in revenue each year. The company earns $-38,960,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. How many employees does Telesis Bio have? The company employs 212 workers across the globe. How can I contact Telesis Bio? The official website for the company is codexdna.com. The company can be reached via phone at 858-228-4115 or via email at ir@codexdna.com. This page (NASDAQ:DNAY) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.